Comparative Pharmacology
Head-to-head clinical analysis: COTRIM versus PYOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COTRIM versus PYOCIDIN.
COTRIM vs PYOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COTRIM is a combination of trimethoprim and sulfamethoxazole; sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, sequentially blocking bacterial folate synthesis.
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
1 double-strength tablet (160 mg trimethoprim + 800 mg sulfamethoxazole) orally every 12 hours for 5-14 days; 15-20 mg/kg/day (based on trimethoprim) IV divided every 6-8 hours for severe infections.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
None Documented
None Documented
Sulfamethoxazole: 9-11 hours (normal renal function); trimethoprim: 8-10 hours. Extended in renal impairment (SMX up to 30h, TMP up to 24h).
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 50-70% unchanged sulfamethoxazole, 15-30% N4-acetylated metabolite; trimethoprim: 50-60% unchanged, 10-20% metabolites. Biliary/fecal: minimal.
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Category C
Category C
Antibiotic
Antibiotic